Metabolic fate of the thrombolytic agent benzarone in man: comparison with the rat and dog
- 1 January 1987
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 17 (7) , 881-896
- https://doi.org/10.3109/00498258709043998
Abstract
1. The metabolic fate of 14C-benzarone in the rat and dog has been compared to that in human subjects. An oral dose was well-absorbed in all three species. However, the 14C excretion patterns differed: humans (100 mg) excreted means of 73 and 19% dose in the urine and faeces respectively, whereas the rat (2 mg/kg) and dog (0.5 mg/kg) excreted > 80% in the faeces, mostly during the first 48 h. 2. Much of the faecal 14C was attributable to 14C excreted in the bile which amounted to 59% in the 7 h bile collected from an intravenously dosed dog, and a mean of 72% in the 24 h bile of orally dosed rats. Enterohepatic circulation of 14C was demonstrated in rats. 3. Total 14C in human plasma reached peak concentrations between 1–2 h and declined relatively rapidly, to about 10% of this value within 24 h. Unchanged benzarone was not detected in plasma (< 25 ng/ml), even after a 400 mg dose, but conjugated benzarone was—accounting for about 10% of the peak concentration of 14C. In the dog, by contrast, conjugated benzarone accounted for about 50% of the peak concentration of 14C of 0.96 μg equiv./ml at 1 h. The extent of binding of benzarone to human plasma proteins (> 99%; in vitro was slightly greater than that (> 96%) of total 14C (ex vivo, representing metabolites). 4. Examination of metabolite profiles by h.p.l.c. suggested that in the rat and dog, at least 70% absorbed dose was eliminated by direct conjugation, whereas in humans at least 70% was hydroxylated before conjugation, mainly with glucuronic acid. Hydroxylation occurred in the benzofuran ring and/or the ethyl side-chain. The principal urinary metabolite in humans was the conjugate(s) of the 1-hydroxylated ethyl side-chain derivative (mean 26% dose).This publication has 11 references indexed in Scilit:
- Metabolism and pharmacokinetics of the dihydropyridine calcium antagonist, ryosidine, in manXenobiotica, 1985
- CHARACTERIZATION AND DETERMINATION OF THE ACTIVITY OF BILIARY BETA-GLUCURONIDASE IN RATS1979
- Metabolism of benzbromarone in manEuropean Journal of Clinical Pharmacology, 1972
- Measurement of Low Energy Beta-Emitters in Aqueous Solution by Liquid Scintillation Counting of Emulsions.Analytical Chemistry, 1965
- RECHERCHES DANS LA SERIE DES BENZOFURANNES .X. ETUDE PHARMACOLOGIQUE ET TOXICOLOGIQUE DE LETHYL-2 (HYDROXY-4'BENZOYL)-3 BENZOFURANNE1965
- RECHERCHES DANS LA SERIE DES BENZOFURANNES .13. TRANSIT DE LETHYL-2 (HYDROXY-4' BENZOYL)-3 BENZOFURANNE CHEZ LHOMME ET CHEZ LANIMAL1965
- RECHERCHES DANS LA SERIE DES BENZOFURANNES .8. EFFETS DE CERTAINS DERIVES BENZOFURANNIQUES SUR LA FRAGILITE ET LA PERMEABILITE CAPILLAIRES1963
- Mesure De La Perméabilité Capillaire Chez Le Rat Technique Et Applications PharmacologiquesArchives Internationales de Physiologie et de Biochimie, 1963